The Role of Toll-like Receptor Agonists and Their Nanomedicines for Tumor ImmunotherapyLingling Huang(Xuzhou Medical College), Zhiyue Zhang(Shandong University)PharmaceuticsJune 10, 202210.3390/pharmaceutics14061228Cited by 52SaveCiteExport RISWatch citationsRelated PapersAnti-Cracking TEOS-Based Hybrid Materials as Reinforcement Agents for Paper Relics|Molecules|2024|15